Pakkianathan Janice, Yamauchi Celina R, Barseghyan Luiza, Cruz Joseph, Simental Alfred A, Khan Salma
Department of Biochemistry, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
Center for Health Disparities & Molecular Medicine, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
J Clin Med. 2025 Apr 23;14(9):2898. doi: 10.3390/jcm14092898.
Anaplastic thyroid carcinoma (ATC) is the rarest and most aggressive form of thyroid cancer, marked by a poor prognosis and resistance to conventional treatments. Like many malignancies, ATC has a complex genetic landscape, with numerous mutations driving tumor initiation, progression, and therapeutic resistance. However, recent advances in molecular research have expanded our understanding of these genetic alterations, paving the way for new targeted treatment strategies. Currently, therapies targeting specific genetic mutations, such as BRAF and MEK, show promise, but their effectiveness is limited to patients harboring these mutations. To explore broader therapeutic possibilities, we conducted a comprehensive literature review using the PubMed database and Google to identify studies on key genetic mutations in ATC. By leveraging these molecular insights, we aim to highlight potential therapeutic avenues that could enhance treatment options and improve patient outcomes.
间变性甲状腺癌（ATC）是甲状腺癌中最罕见且侵袭性最强的一种，其特征是预后不良且对传统治疗有抗性。与许多恶性肿瘤一样，ATC具有复杂的基因图谱，众多突变驱动肿瘤的起始、进展和治疗抗性。然而，分子研究的最新进展扩展了我们对这些基因改变的理解，为新的靶向治疗策略铺平了道路。目前，针对特定基因突变（如BRAF和MEK）的疗法显示出前景，但它们的有效性仅限于携带这些突变的患者。为了探索更广泛的治疗可能性，我们使用PubMed数据库和谷歌进行了全面的文献综述，以确定关于ATC关键基因突变的研究。通过利用这些分子见解，我们旨在突出潜在的治疗途径，这些途径可以增加治疗选择并改善患者预后。
